Operating profit at GSK fell by 86 per cent due to a charge related to the settlement of Zantac settlements the company said ...

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

While the scientific consensus remains that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, GSK strongly believes that these settlements are in the ...

In a statement following the announcement, GSK reiterated its stance on the scientific evidence regarding Zantac and outlined ...

The pharmaceutical giant reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance ...

GSK has steadfastly denied that Zantac causes cancer, pointing to the lack of any reliable evidence in 16 epidemiological studies investigating a link, and stressed that the settlements have been ...

Shares of the UK-based pharma giant GlaxoSmithKline PLC (GB:GSK) soared over 6% after the company announced a settlement of up to $2.2 billion for Zantac lawsuits in the U.S. The settlement ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

"Dismissal of 93% of cases for $2.2bn nears our best case scenario, and should remove the majority of Zantac overhang on the stock. Importantly we believe the settlement cost is also well below ...

Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE ...